GM-CSF autoantibodies in plasma clearly differentiated patients with aPAP, healthy volunteers and patients with COPD or asthma without aPAP: patients with aPAP had high levels, as expected, while levels in other study populations were too low to quantify. The gene discussed is CSF2; the disease is autoimmune pulmonary alveolar proteinosis.